Literature DB >> 2887325

Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.

W Kirch, I Rose, H G Demers, G Leopold, J Pabst, E E Ohnhaus.   

Abstract

The pharmacokinetics of bisoprolol were investigated following oral administration of 10mg once daily for 7 days in 8 healthy subjects, in 14 patients with different degrees of renal impairment and in 18 patients with liver disease. In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10.0 hours and total body clearance of 14.2 L/h were observed. 5.21 mg/24 hours of unchanged bisoprolol were recovered following urinary excretion during the dosage interval. In 11 patients with renal impairment (mean CLCR = 28 +/- 5 ml/min/1.72m2) half-life was prolonged to 18.5 hours, and peak and trough concentrations were 74 and 32 micrograms/L, respectively. Correspondingly, urinary excretion decreased to 3.35 mg/24 hours and total body clearance to 7.8 L/h. In uraemic patients (CLCR less than 5 ml/min/1.73m2) the total clearance of bisoprolol was 5.0 L/h and the elimination half-life was 24.2 hours. In patients with liver cirrhosis half-life increased to 13.5 hours, steady-state peak and trough concentrations increased to 62 and 22 micrograms/L, respectively, and total body clearance decreased to 10.8 L/h. The present study indicates that in patients with impairment of kidney or liver function accumulation of bisoprolol above a factor of 2 did not occur. However, in the terminal stages of insufficiency of kidney or liver function bisoprolol dosage should not exceed 10mg.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2887325     DOI: 10.2165/00003088-198713020-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  12 in total

1.  Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin.

Authors:  E E Ohnhaus; B Kirchhof; E Peheim
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

2.  Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.

Authors:  G Leopold; J Pabst; W Ungethüm; K U Bühring
Journal:  J Clin Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.126

3.  Pharmacokinetics of atenolol in relation to renal function.

Authors:  W Kirch; H Köhler; E Mutschler; M Schäfer
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

4.  Beta-adrenoceptor-blocking agents: pharmacokinetic differences and their clinical implications illustrated on pindolol.

Authors:  J Meier
Journal:  Cardiology       Date:  1979       Impact factor: 1.869

5.  Clinical experience with atenolol in patients with chronic liver disease.

Authors:  W Kirch; M Schäfer-Korting; E Mutschler; E E Ohnhaus; W Braun
Journal:  J Clin Pharmacol       Date:  1983-04       Impact factor: 3.126

6.  The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.

Authors:  W Kirch; H Köhler; G Berggren; W Braun
Journal:  Clin Nephrol       Date:  1982-08       Impact factor: 0.975

7.  Pharmacokinetics of atenolol in patients with renal impairment.

Authors:  J Sassard; N Pozet; J McAinsh; J Legheand; P Zech
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

8.  Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.

Authors:  H J Schliep; J Harting
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

9.  Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function.

Authors:  L Jordö; P O Attman; M Aurell; L Johansson; G Johnsson; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

10.  Interaction of bisoprolol with cimetidine and rifampicin.

Authors:  W Kirch; I Rose; I Klingmann; J Pabst; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more
  18 in total

1.  Pharmacokinetics and safety of cicloprolol in uraemic patients.

Authors:  J P Fillastre; M Aparicio; C Porquet; C Dubruc; P Rosenzweig; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 4.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

6.  β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Authors:  Alvin Tieu; Thomas J Velenosi; Andrew S Kucey; Matthew A Weir; Bradley L Urquhart
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

Review 7.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

8.  Population pharmacokinetics of bisoprolol in patients with chronic heart failure.

Authors:  Valentina N Nikolic; Tatjana Jevtovic-Stoimenov; Radmila Velickovic-Radovanović; Stevan Ilic; Marina Deljanin-Ilic; Dragan Marinkovic; Svetlana Apostolović; Dragana Stanojevic; Slavoljub Zivanovic; Nikola Stefanovic; Srdjan Pesic; Dejana Ruzic Zecevic; Jasmina R Milovanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

9.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

10.  Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study.

Authors:  Katja Cvan Trobec; Iztok Grabnar; Mojca Kerec Kos; Tomaz Vovk; Jurij Trontelj; Stefan D Anker; Giuseppe Rosano; Mitja Lainscak
Journal:  Eur J Clin Pharmacol       Date:  2016-03-21       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.